Chronic Kidney Disease Improvement in Research and Treatment Act of 2023
Latest Action
Referred to the Subcommittee on Health.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Chronic Kidney Disease Improvement in Research and Treatment Act of 2023 (H.R. 5027) is a legislative proposal introduced in the House during the 118th Congress aimed at enhancing research and treatment efforts related to chronic kidney disease. The bill's specific provisions, including detailed measures or funding allocations, are not provided in the available data. As of December 17, 2024, the bill was referred to the Subcommittee on Health but ultimately failed or expired without becoming law. The policy area focuses on health, specifically targeting improvements in chronic kidney disease outcomes through research and treatment advancements.
H.R. 5027 sought to improve chronic kidney disease research and treatment but did not advance beyond subcommittee referral and expired without enactment.
- The bill is focused on chronic kidney disease within the health policy area.
- It was introduced in the House of Representatives during the 118th Congress.
- The latest recorded action was referral to the Subcommittee on Health on December 17, 2024.
- The bill ultimately failed or expired without further legislative progress.
- No official summary or full text details are available to clarify specific provisions.
['Patients with chronic kidney disease who may benefit from improved research and treatment options.', 'Health agencies and research institutions involved in kidney disease studies.', 'Healthcare providers specializing in nephrology and chronic kidney disease management.']
['Lack of detailed information on funding mechanisms or authority limits may pose challenges for implementation.', 'Without full text or summary, oversight and enforcement provisions cannot be assessed.', "The bill's failure to advance suggests potential legislative or policy hurdles."]
The bill was introduced in the House during the 118th Congress and referred to the Subcommittee on Health. It did not progress beyond this stage and expired, indicating limited legislative momentum or prioritization within the congressional session. The focus on chronic kidney disease aligns with ongoing health policy discussions about improving treatment and research for chronic conditions.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
["Potential increased awareness of chronic kidney disease issues among lawmakers and health stakeholders despite the bill's failure.", 'Possible influence on future legislative proposals addressing chronic kidney disease research and treatment.', 'Continued reliance on existing programs and policies for chronic kidney disease management due to lack of new legislative action.']
The absence of an official summary and full bill text limits transparency and public understanding of the bill's intended measures and potential impacts. The bill's failure to advance beyond subcommittee referral highlights the importance of tracking legislative progress to assess policy developments. Future transparency efforts would benefit from comprehensive documentation to enable thorough analysis and oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.